Skip to main content
BMC Infectious Diseases logoLink to BMC Infectious Diseases
. 2020 Feb 26;20:177. doi: 10.1186/s12879-020-4825-2

Factors associated with antibiotic prescribing for acute bronchitis at a university health center

Valerie J Morley 1, Emily P C Firgens 2, Rachel R Vanderbilt 2, Yanmengqian Zhou 2, Michelle Zook 3, Andrew F Read 1,4,5, Erina L MacGeorge 2,
PMCID: PMC7045376  PMID: 32102652

Abstract

Background

Antibiotics are not indicated for treating acute bronchitis cases, yet up to 70% of adult acute bronchitis medical visits in the USA result in an antibiotic prescription. Reducing unnecessary antibiotic prescribing for acute bronchitis is a key antibiotic stewardship goal set forth by the Centers for Disease Control and Prevention. Understanding what factors influence prescribing for bronchitis cases can inform antimicrobial stewardship initiatives. The goal of this study was to identify factors associated with antibiotic prescribing at a high-volume student health center at a large US university. The Pennsylvania State University Health Services offers on-campus medical care to a population of over 40,000 students and receives over 50,000 visits every year.

Methods

We conducted a retrospective chart review of acute bronchitis visits for the 2015–2016 academic year and used a multivariate logistic regression analysis to identify variables associated with antibiotic prescribing.

Results

Findings during lung exams increased the likelihood of an antibiotic prescription (rales OR 13.95, 95% CI 3.31–80.73; rhonchi OR 5.50, 95% CI 3.08–10.00; percussion abnormality OR 13.02, 95% CI 4.00–50.09). Individual clinicians had dramatically different rates of prescribing (OR range 0.03–12.3). Male patients were more likely than female patients to be prescribed antibiotics (OR 1.68, 95% CI 1.17–2.41). Patients who reported longer duration since the onset of symptoms were slightly more likely to receive prescriptions (OR 1.04 per day, 95% CI 1.03–1.06), as were patients who reported worsening symptoms (OR 1.78, 95% CI 1.03–3.10). Visits with diagnoses or symptoms associated with viral infections or allergies were less likely to result in prescriptions (upper respiratory tract infection (URI) diagnosis OR 0.33, 95% CI 0.18–0.58; sneezing OR 0.39, 95% CI 0.17–0.86; vomiting OR 0.31, 95% CI 0.10–0.83). An exam finding of anterior cervical lymphadenopathy was associated with antibiotic prescribing (tender OR 3.85, 95% CI 1.70–8.83; general OR 2.63, 95% CI 1.25–5.54).

Conclusions

Suspicious findings during lung examinations (rales, rhonchi, percussion abnormality) and individual healthcare providers were important factors influencing antibiotic prescribing rates for acute bronchitis visits. Patient gender, worsening symptoms, duration of illness, symptoms associated with viral infections or allergies, and anterior cervical lymphadenopathy also influenced prescribing rates.

Keywords: Antibiotic stewardship, Antibiotic prescribing, Acute bronchitis, Respiratory tract infections, Student health

Background

In the United States, 30% of outpatient antibiotic prescribing is estimated to be unnecessary, resulting in almost 47 million unnecessary antibiotic prescriptions each year [1, 2]. Excessive antibiotic prescribing drives the spread of antibiotic resistance, which contributes to increased morbidity, mortality, and economic costs associated with infections [35]. In response, the 2015 U.S. National Action Plan for Combatting Antibiotic-Resistant Bacteria set a goal of reducing inappropriate antibiotic prescribing in outpatient settings by 50% by 2020 [6].

A major source of unnecessary outpatient antibiotic prescriptions is acute bronchitis cases [710]. Acute bronchitis is a common self-limited respiratory illness, characterized predominantly by cough, typically lasting less than 3 weeks [7, 11]. In the US in 2011, cough was the most common illness-related reason for ambulatory care visits, accounting for 2.6 million outpatient visits [12]. A study in the UK estimated that 44/1000 adults are affected by acute bronchitis each year [13]. Antibiotics are not effective for treating acute bronchitis, which is usually of viral etiology [11], and long-standing professional guidelines recommend against antibiotics for uncomplicated cases [14, 15]. Nevertheless, US adults are prescribed antibiotics for acute bronchitis approximately 60–70% of the time [79, 16]. Further, relative to other upper respiratory tract infections for which antibiotic treatment is not indicated (e.g., nasopharyngitis, laryngitis), providers are especially likely to prescribe for acute bronchitis [8, 1720]. Due to the prevalence of overprescribing, the U.S. Centers for Infectious Disease Control (CDC) has identified acute bronchitis cases as a major opportunity for reducing unnecessary outpatient antibiotic prescribing [21].

Although acute bronchitis presents an opportunity to improve antibiotic stewardship, there is little consensus regarding effective stewardship interventions for ambulatory care [2224]. A diversity of interventions have been proposed, but evidence supporting their effectiveness remains sparse [23, 24]. Implementation of outpatient stewardship programs could be aided by identifying the factors driving overprescribing, which might point to interventions that target those drivers [22]. Factors driving antibiotic overprescribing may differ between hospital and outpatient settings and could include diagnostic uncertainty, real or perceived patient expectations for antibiotics, time pressures, or gaps in provider knowledge [25, 26].

Identifying drivers of prescribing for acute bronchitis could suggest potential interventions, but relatively few studies have focused on identifying these predictors. Prior studies of upper respiratory tract infection prescribing (including for acute bronchitis) in the USA have shown higher rates of antibiotic prescribing in rural (vs. urban) practices [8, 10], when patients have multiple diagnoses [27] or illness of longer duration [28], when providers are advanced practitioners rather than physicians [9], and when providers experience greater diagnostic uncertainty [27]. Since most studies have utilized data reported to insurance companies or national agencies [13, 16, 23], few previous studies have examined how physical exam findings influence prescribing for acute bronchitis. In the few studies that have included data from patient charts, purulent nasal discharge, purulent sputum, abnormal respiratory exam, tonsillar exudate, and sinus tenderness have been reported to be moderately associated with prescribing [20, 29]. In addition, US prescribing rates for uncomplicated acute bronchitis are higher for younger adults (18–39) than older adults (40+) [16], suggesting that factors influencing bronchitis prescribing for young adults are particularly good targets for evaluation and intervention.

University student health clinics provide an opportunity to study antibiotic prescribing in young adult patient populations. In the US, college students comprise a sizeable cohort of the population, with 20.1 million students enrolled in higher education, including 13.8 million students enrolled at 4-year degree-granting institutions [30]. At these 4-year institutions, there are 165.5 annual visits to student health centers for every 100 enrolled students, 37% of which are for respiratory tract infections [31]. Despite evidence that unnecessary antibiotic prescribing is high in young adult populations [16], antibiotic stewardship programs are almost nonexistent at most student health centers, and best stewardship practices are not yet defined. Understanding what drives unnecessary antibiotic prescribing in student health centers is a first step towards evidence-based stewardship policies in these settings, and findings can also inform stewardship efforts with providers treating young adults in similar contexts (e.g., urgent care clinics).

The goal of this study was to identify patient and visit factors associated with antibiotic prescribing for young adults diagnosed with acute bronchitis at a high-volume student health center at a large US university. We conducted a retrospective chart review of all visits with an acute bronchitis diagnosis for the 2015–2016 academic year at the Pennsylvania State University’s Student Health Center. This work is part of a multi-study interdisciplinary effort to improve antibiotic stewardship in emerging adult populations, with an initial focus on students at residential colleges.

Methods

Study site

The Pennsylvania State University Health Services (UHS) offers on-campus medical care to PSU students and their dependents, serving over 40,000 students in more than 50,000 visits yearly. At the time of the study, 28 clinicians saw patients at UHS. During the study period, 21 of these clinicians (9 doctors of medicine (MDs), 2 doctors of osteopathic medicine (DOs), 8 physician assistants (PAs), and 2 nurse practitioners (NPs)) diagnosed at least one patient with acute bronchitis. The remaining clinicians did not diagnose acute bronchitis in the period studied, and therefore they do not appear in the data set.

Data collection and Curation

UHS staff identified 1451 visits with acute bronchitis diagnoses during the 2015–2016 academic year (August–May). Honest brokers were then employed and trained to access the electronic medical records for these visits, extract deidentified data (data excluding information that could be used to identify individual patients), and enter it in the secure database manager REDCap for use by the researchers. Data extracted included patient characteristics, visit characteristics, symptoms recorded, exam findings, secondary diagnoses, tests ordered, and antibiotic prescriptions (see Table 1). A double-entry procedure was used to provide a reliability check on data extracted from a randomly selected sample (N = 69; ~ 5%) of the visits. This check indicated adequate data quality (agreement > 96% across all variables) for the intended analyses; identified discrepancies were corrected [3234].

Table 1.

Descriptive statistics (n = 1031) and bivariate analysis

Variable Visit Count (%) Odds Ratio (95% CI) Bivariate
p-value
Date and Time
 visit date 1028 (99.7%) 0.99 (0.99-0.99) p < 0.001 **
 week day 1028 (99.7%) range 0.64-1.28 p = 0.63
 time of day 1021 (99.0%) 0.99 (0.99-0.99) p = 0.24
Patient Characteristics
 gender p = 0.03*
  female (reference group) 636 (61.7%) -
  male 390 (37.8%) 1.34 (1.02-1.76)
  not recorded 5 (0.5%) -
 race p = 0.43
  white (reference group) 594 (57.6%) -
  multiple 92 (8.9%) 0.90 (0.55-1.44)
  Asian 50 (4.8%) 0.97 (0.51-1.79)
  black 21 (2.0%) 1.04 (0.38-2.54)
  Hispanic 6 (0.6%) -
  international 7 (0.7%) -
  Pacific islander 1 (0.1%) -
  not recorded 260 (25.2%) -
 academic status p = 0.27
  undergraduate student 932 (90.4%) -
  graduate student 85 (8.2%) 0.86 (0.52-1.39)
  spouse/dependent 3 (0.3%) -
  not recorded 11 (1.1%) -
 height (inches) 1013 (98.2%) 1.04 (1.00-1.08) p = 0.02*
 weight (pounds) 1016 (98.5%) 1.00 (0.99-1.01) p = 0.09
Visit Characteristics
 provider see Fig 3 range 0.05–4.63 p < 0.001**
 days since onset (patient reported) †† 1016 (98.5%) 1.02 (1.01-1.03) p < 0.001**
 severity (patient reported) p = 0.009*
  mild (reference group) 61 (5.9%) -
  moderate 342 (33.2%) 0.48 (0.27-0.86)
  severe 32 (3.1%) 1.13 (0.46-2.70)
  not recorded 596 (57.8%) -
 progression (patient reported) p < 0.001**
  stable/no change (reference group) 274 (26.6%) -
  worsening 317 (30.7%) 2.27 (1.77-3.77)
  improving 108 (10.5%) 1.06 (0.60-1.84)
  not recorded 332 (32.2%) -
 antibiotics in past month 40 (3.9%) 0.46 (0.19-1.00) p = 0.07
Additional Diagnosis
 upper respiratory infection 197 (19.1%) 0.26 (0.16-0.39) p < 0.001**
 suspicious cough 77 (7.5%) 1.02 (0.61-1.67) p = 0.93
 allergic rhinitis 32 (3.1%) 0.51 (0.19-1.17) p = 0.14
 fever 17 (1.6%) 2.58 (0.98-6.92) p = 0.05
 viral syndrome 13 (1.3%) - -
 tonsillitis 6 (0.6%) - -
 influenza 4 (0.4%) - -
 mononucleosis 3 (0.3%) - -
Common Symptoms Recorded†
 throat symptoms
  sore throat 402 (39.0%) 1.42 (1.08-1.85) p = 0.01*
  painful swallowing 130 (12.6%) 0.58 (0.37-0.89) p = 0.02*
  hoarseness 167 (16.2%) 0.80 (0.55-1.56) p = 0.25
  swollen glands in neck 112 (10.9%) 1.08 (0.70-1.63) p = 0.73
 systemic symptoms
  headache 244 (23.7%) 0.79 (0.57-1.09) p = 0.15
  documented fever 68 (6.6%) 0.70 (0.42-1.17) p = 0.17
  fever symptoms (patient reported) 255 (24.7%) 0.94 (0.69-1.28) p = 0.71
  chills 147 (14.2%) 0.94 (0.65-1.37) p = 0.73
  sweats 159 (15.4%) 1.19 (0.82-1.75) p = 0.36
 nasal symptoms
  stuffy nose 665 (64.5%) 0.86 (0.66-1.14) p = 0.29
  sinus congestion 344 (33.4%) 0.73 (0.55-0.98) p = 0.03*
  clear nasal discharge 215 (20.9%) 0.71 (0.50-0.99) p = 0.04*
  purulent nasal discharge 184 (17.8%) 0.83 (0.58-1.19) p = 0.33
  post-nasal drip sensation 390 (37.8%) 0.93 (0.70-1.21) p = 0.59
  sinus pain 79 (7.7%) 1.69 (1.05-2.69) p = 0.03*
  sneezing 101 (9.8%) 0.39 (0.22-0.66) p < 0.001**
 pulmonary symptoms
  sleep disruption due to cough 610 (59.2%) 1.22 (0.93-1.59) p = 0.15
  sputum production 638 (61.9%) 0.98 (0.75-1.29) p = 0.91
  shortness of breath 348 (33.8%) 0.74 (0.56-0.97) p = 0.03*
  chest tightness 277 (26.8%) 0.94 (0.69-1.26) p = 0.67
  wheezing 275 (26.7%) 0.64 (0.48-0.86) p = 0.003*
  chest pain 232 (22.5%) 0.82 (0.60-1.12) p = 0.22
  paroxysms of cough 315 (30.6%) 0.98 (0.73-1.30) p = 0.87
 ear symptoms
  ear pain 48 (4.7%) 1.02 (0.53-1.88) p = 0.94
  ear pressure sensation 122 (11.8%) 0.89 (0.58-1.35) p = 0.60
  decreased hearing 34 (3.3%) 0.81 (0.35-1.69) p = 0.58
 GI symptoms
  loss of appetite 129 (12.5%) 0.82 (0.54-1.23) p = 0.34
  abdominal pain 25 (2.4%) 0.30 (0.07-0.87) p = 0.05
  post-tussive vomiting 74 (7.2%) 0.67 (0.41-1.09) p = 0.10
  nausea 63 (6.1%) 0.46 (0.22-0.86) p = 0.02*
  vomiting 48 (4.6%) 0.44 (0.19-0.89) p = 0.03*
  diarrhea 34 (3.3%) 1.24 (0.59-2.49) p = 0.56
 neuro-vascular symptoms
  lightheadedness 47 (4.6%) 1.29 (0.69-2.35) p = 0.41
Commonly Ordered Labs
 chest x-ray 177 (17.2%) 2.09 (1.50-2.90) p < 0.001**
 rapid strep screen 31 (3.0%) 0.65 (0.26-1.45) p = 0.32
 complete blood count 85 (8.2%) 1.40 (0.88-2.21) p = 0.15
 Monospot 27 (2.6%) 1.83 (0.83-3.95) p = 0.12
 influenza A + B 16 (1.6%) 0.32 (0.05-1.14) p = 0.13
Common Exam Findings†
 ear exam
  tympanic membrane (TM) 27 (2.6%) 0.08 (0.004-0.40) p = 0.01*
 bulging
  TM retraction 42 (4.1%) 0.79 (0.38-1.55) p = 0.51
  visible fluid behind TM 148 (14.3%) 0.17 (0.09-0.29) p < 0.001**
  cerumen in canal 29 (2.8%) 0.46 (0.15-1.12) p = 0.12
 nose exam
  mucosal edema 580 (56.2%) 0.83 (0.63-1.08) p = 0.16
  mucosal erythema 510 (49.5%) 0.78 (0.59-1.01) p = 0.06
  nasal discharge 324 (31.4%) 1.59 (1.20-2.09) p = 0.001**
  maxillary sinus tenderness 30 (2.9%) 1.75 (0.83-3.64) p = 0.13
 throat exam
  erythema 209 (20.3%) 0.79 (0.56-1.10) p = 0.17
  lymphoid hyperplasia 104 (10.1%) 1.47 (0.96-2.22) p = 0.07
  post-nasal drip 157 (15.2%) 1.44 (1.00-2.04) p = 0.04*
tonsil exam
  surgically absent 42 (4.1%) 1.13 (0.57-2.14) p = 0.71
  erythema 84 (8.1%) 0.43 (0.23-0.74) p = 0.004**
  enlarged 47 (4.5%) 1.17 (0.62-2.32) p = 0.64
 lymphatics exam
  anterior cervical lymphadenopathy, tender 53 (5.1%) 1.93 (1.10-3.38) p = 0.02*
  anterior cervical lymphadenopathy, non-tender 87 (8.4%) 0.70 (0.41-1.14) p = 0.16
  posterior cervical lymphadenopathy, non-tender 51 (4.9%) 0.60 (0.29-1.16) p = 0.15
  anterior cervical lymphadenopathy 99 (9.6%) 3.05 (2.01-4.66) p < 0.001**
  posterior cervical lymphadenopathy 26 (2.5%) 1.00 (0.41-2.25) p = 0.10
 lung exam
  wheezing 215 (20.9%) 1.92 (1.40-2.61) p < 0.001**
  rales 21 (2.0%) 10.05 (3.69-35.18) p < 0.001**
  rhonchi 223 (21.6%) 2.33 (1.71-3.16) p < 0.001**
  percussion abnormality 25 (2.4%) 9.55 (3.83-28.91) p < 0.001**

We subsequently excluded data on 271 follow-up visits within UHS for previously diagnosed conditions and 149 visits with additional diagnoses for which antibiotics might be appropriate (sinusitis, pharyngitis, streptococcal pharyngitis, otitis media). One thousand thirty-one visits were included in the final analysis (Fig. 1).

Fig. 1.

Fig. 1

Flow of study inclusion and exclusion criteria for acute bronchitis visits (n = number of visits). Side arrows indicate exclusion criteria

Data from electronic patient charts included variables for all symptoms and exam findings listed in the record system. Many of these symptoms (e.g. eye discharge, mouth sores) were uncommon in acute bronchitis visits. To narrow the list to variables that might be important in acute bronchitis visits, as well as to eliminate variables with zero frequency cells in univariate contingency tables, we only considered symptoms and exam findings recorded for > 20 patients for subsequent analysis (Table 1).

Four visits had onset durations that were extreme outliers (> 100 days since onset), and we substituted missing values for these onset durations. Models excluded visits with missing values in predictor variables. This strategy resulted in 33 visits being excluded from analysis in the final multivariate model due to missing values in predictor variables. It is important to note that for two patient-reported variables, severity and progression, “not recorded” was coded as a factor level, and these entries were not considered missing values.

Statistical methods

In all analyses, the response variable was whether an antibiotic was prescribed at a visit. All variables listed in Table 1 were tested as possible predictive factors. Bivariate logistic regression analyses were used to identify a narrowed list of potential predictors of antibiotic prescribing (Table 1) [35]. Provider traits were not included in the logistic regression analysis due to the small number of providers in the data set (21 total). All variables identified as significant in the bivariate analyses were entered into multivariate logistic regression analyses to identify independent predictors of antibiotic prescribing for acute bronchitis. Backward stepwise removal of nonsignificant variables was used to generate the final multivariate model [35]. Factors were considered significant in the regression analyses when they had p-values < 0.05. Analyses were carried out using R (version 3.4.3).

Results

Study population and antibiotic prescribing

The data set included 1031 visits with an acute bronchitis diagnosis (Table 1). 61.7% of patients were female, and 90.1% of patients were undergraduate students. Antibiotics were prescribed at 30.8% of visits. Azithromycin was the most commonly prescribed antibiotic (83.9% of prescriptions) (Fig. 2a). Figure 2b shows the distribution of acute bronchitis visits and rates of antibiotic prescribing over the course of the 2015–2016 academic year. Table 1 shows the frequency of antibiotic prescribing by variable.

Fig. 2.

Fig. 2

Antibiotic prescribing. a Antibiotic prescriptions by drug. b Visits and antibiotic prescribing over time

Factors associated with antibiotic use

Factors independently associated with antibiotic prescribing in a multivariate regression model are summarized in Table 2. The factors with the greatest impacts on prescribing were individual providers and suspicious findings during lung examinations. The 21 providers in the data set had dramatically different rates of prescribing for acute bronchitis cases ranging from 0 to 80% (Fig. 3), and provider was an important predictor of prescribing (odds ratios (OR) ranged from 0.03 to 12.3 for individual providers). Suspicious findings during lung examinations were highly associated with antibiotic prescribing (rales OR 13.95, 95% CI 3.31–80.73; rhonchi OR 5.50, 95% CI 3.08–10.00; percussion abnormality OR 13.02, 95% CI 4.00–50.09).

Table 2.

Factors independently associated with prescribing in a multivariate model

Variable Odds Ratio (95% CI) p-value
Visit and Patient Characteristics
 visit date (days) 0.99 (0.99-0.99) p < 0.001**
 gender
  female (reference group)
  male 1.68 (1.17-2.41) p = 0.005**
 provider 0.03-12.3 p < 0.001**
 onset duration (days) 1.04 (1.03-1.06) p < 0.001**
 progression
  stable/no change (reference group)
  worsening 1.78 (1.03-3.10) p = 0.04*
  improving 0.74 (0.35-1.54) p = 0.43
  not recorded 1.69 (0.87-3.27) p = 0.12
Additional Diagnosis
 URI diagnosis 0.33 (0.18-0.58) p < 0.001**
Symptoms
 sneezing 0.39 (0.17-0.86) p = 0.02*
 vomiting 0.31 (0.10-0.83) p = 0.03*
Exam Findings
 lymphatics
  anterior cervical lymphadenopathy, tender 3.85 (1.70-8.83) p = 0.001**
  anterior cervical lymphadenopathy 2.63 (1.25-5.54) p = 0.01*
 lungs
  rales 13.95 (3.31-80.73) p = 0.001**
  rhonchi 5.50 (3.08-10.00) p < 0.001**
  percussion abnormality 13.02 (4.00-50.09) p < 0.001**

Fig. 3.

Fig. 3

Antibiotic prescribing rates by provider. Prescribing rates for acute bronchitis visits were highly variable among providers. The total number of acute bronchitis visits for each provider is shown above the bar, together with the national average [79, 16], and the overall rate at the PSU health facility

The model showed that prescribing rates decreased slightly over the course of the academic year (OR 0.99 per day, 95% CI 0.99–0.99). Male patients were more likely than female patients to be prescribed antibiotics (OR 1.68, 95% CI 1.17–2.41). Patients who reported longer duration since the onset of symptoms were slightly more likely to receive prescriptions (OR 1.04 per day, 95% CI 1.03–1.06), as were patients who reported their symptoms were worsening (OR 1.78, 95% CI 1.03–3.10). Visits with additional diagnoses or symptoms associated with viral infections or allergies were less likely to result in prescriptions (URI diagnosis OR 0.33, 95% CI 0.18–0.58; sneezing OR 0.39, 95% CI 0.17–0.86; vomiting OR 0.31, 95% CI 0.10–0.83). An exam finding of anterior cervical lymphadenopathy was associated with antibiotic prescribing (tender OR 3.85, 95% CI 1.70–8.83; general OR 2.63, 95% CI 1.25–5.54).

As a check, we repeated these analyses without excluding the data from follow-up visits (N = 149) for previously diagnosed conditions (Figure 4 in Appendix). The results of this analysis were qualitatively similar to the primary analysis, with the addition of antibiotic prescriptions in the past month as a predictor of prescribing (Tables 3 and 4 in Appendix). Patients who reported taking antibiotics in the past month were less likely to be prescribed antibiotics (OR 0.31, 95% CI 0.14–0.66). Provider and lung exam findings were the strongest predictors of prescribing in both analyses. Visit date, duration since onset, progression, URI diagnosis, sneezing, and anterior cervical lymphadenopathy were also significant predictors in both analyses.

Discussion

This study’s results indicated two key drivers of antibiotic prescribing: variation between individual providers and diagnostic uncertainty. We take each of these in turn. Individual providers had extraordinarily variable rates of antibiotic prescribing for acute bronchitis (ranging from 0 to 80%), despite treating the same patient population at the same clinic. These results suggest that a subset of providers can drive a disproportionate amount of unnecessary antibiotic prescribing for acute bronchitis. In the current study, provider traits (e.g. provider specialty, age) were not included in the logistic regression analysis due to the small number of providers in the data set (21 total). Previous studies have identified provider specialty, provider age, and perceived patient demand for antibiotics as factors influencing provider prescribing rates for upper respiratory tract infections [9, 20, 26, 36, 37].

A second important driver may be diagnostic uncertainty. In the present study, prescriptions were much more likely when findings of rales, rhonchi, or percussion abnormalities were recorded during lung examination, and somewhat more likely when external anterior cervical lymphadenopathy was reported. Rales and percussion abnormalities increased prescribing 13-fold, and rhonchi increased prescribing 5-fold. This increase in prescribing may reflect suspicion of pneumonia. Orders of chest x-rays, which also indicate suspicion of pneumonia, were a significant predictor of prescribing in a bivariate analysis, but were not significant in a multivariate model due to high correlation with other lung exam findings. Providers may prescribe antibiotics when there is suspicion of a condition that would respond to antibiotics or general diagnostic uncertainty [27], and this may not be reflected in the diagnosis code.

Other predictors of prescribing in this study included symptoms of sneezing and vomiting, reported worsening of symptoms, diagnosis of an upper respiratory tract infection, duration of illness, and patient gender. Duration of illness has previously been associated with prescribing for upper respiratory tract infections [28]. Patient gender has not typically been associated with prescribing rates for acute bronchitis [16, 20, 28, 29], although some studies have reported that males are more likely to get antibiotic prescriptions for upper respiratory tract infections [8, 17].

The identification of provider variation and diagnostic uncertainty as drivers of prescribing suggests possible interventions for this clinic and similar settings. Provider variation points to a need for provider-targeted interventions such as audit and feedback, communication training, provider education, or clinical decision support tools [22, 23]. In an ‘audit and feedback’ intervention, individual clinicians receive personalized, ongoing feedback on their prescribing rates [2224, 38, 39]. In one study, quarterly feedback resulted in a 50% relative reduction in broad-spectrum antibiotic use for respiratory tract infections [24]. Provider communication training has also been shown to decrease unnecessary antibiotic prescribing [23]. Communication training addresses provider concerns related to patient satisfaction and patient expectation for antibiotics [23]. In some cases, diagnostic uncertainty may be addressed through point of care diagnostic testing [22]. Point of care diagnostics are available for respiratory tract infections including Group A Streptococcus and influenza [22]. There is some evidence supporting point of care testing to reduce antibiotic prescribing for respiratory tract infections [23, 40].

While unnecessary prescribing for acute bronchitis was common in our data, the rate of prescribing was substantially lower than the nationwide average. In the 2015–2016 academic year, antibiotics were prescribed at less than a third of acute bronchitis visits, compared to national rates near 70% [79, 16]. There is still room for improvement, but overall, this suggests that lower rates of prescribing for acute bronchitis are achievable.

Our study is unique in its focus on antibiotic prescribing practices at a university health center. University health services are important centers for antibiotic prescribing serving millions of patients, yet they have largely been overlooked as sites for antibiotic stewardship. To our knowledge, the Pennsylvania State University is the first university with a student antibiotic stewardship program. This study is the first to identify drivers of antibiotic prescribing in a university health center, and one of the few to focus on young adults or consider exam findings and symptoms from patient charts as possible predictors of prescribing. We hope that these findings can be used to inform antibiotic stewardship initiatives at university health centers and similar clinical contexts. Our results suggest that unnecessary antibiotic prescribing is disproportionately driven by a subset of clinicians, and interventions targeting providers may be effective at reducing unnecessary prescribing.

Conclusions

Reducing unnecessary antibiotic prescribing for acute bronchitis cases is a national antibiotic stewardship goal, yet rates of unnecessary antibiotic prescribing remain stubbornly high nationwide. Here we identified factors that influence antibiotic prescribing for acute bronchitis cases at a large university health center. Suspicious findings during lung examinations (rales, rhonchi, percussion abnormality) and individual healthcare providers were the most influential factors affecting antibiotic prescribing rates for acute bronchitis visits. Patient gender, worsening symptoms, duration of illness, symptoms associated with viral infections or allergies, and anterior cervical lymphadenopathy also influenced prescribing rates.

Acknowledgments

We are grateful to the University Health Services Antibiotic Stewardship committee for their enthusiastic support. Karen Bascom, Karen Anderson, and Julia Lundy were instrumental to data entry. Ruth Anne Snyder, Bettyann Milliron, Carmel Kamens, and Cristie Happekotte helped coordinate access and training for the honest brokers. We also thank Sue Johnson for her help and support with computing. This study grew out of discussions initiated by Lewis Logan. We thank reviewers Katherine Ka Wai Lam, Yu Feng, and Sofiane Bakour and editor Simon Ching Lam for their helpful comments on this manuscript.

Abbreviations

GI

Gastrointestinal

PSU

Pennsylvania State University

TM

Tympanic membrane

UHS

University Health Services

URI

Upper respiratory tract infection

Appendix

Analysis including follow-up visits

The logistic regression analyses described in the main text were repeated with a data set including follow-up visits for previously diagnosed conditions, which had been excluded from the original analysis. Antibiotics were prescribed at 30.0% of visits.

Fig. 4.

Fig. 4

Flow of study inclusion and exclusion criteria for acute bronchitis visits (n = number of visits). Side arrows indicate exclusion criteria

Table 3.

Descriptive statistics (n = 1270) and bivariate analysis

Variable Visits Odds Ratio (95% CI) Bivariatep-value
Date and Time
 visit date 1267 (99.8%) 0.99 (0.99-0.99) p < 0.001 **
 week day 1267 (99.8%) range 0.60-1.40 p = 0.26
 time of day 1258 (99.0%) 0.99 (0.99-1.00) p = 0.61
Patient Characteristics
 gender p = 0.07
  female (reference group) 788 (62.0%) -
  male 477 (46.3%) 1.25 (0.98-1.60)
  not recorded 5 (0.4%) -
 race p = 0.20
  white (reference group) 737 (58.0%) -
  multiple 117 (9.2%) 0.76 (0.48-1.17)
  Asian 61 (4.8%) 0.88 (0.49-1.54)
  black 31 (2.4%) 1.00 (0.45-2.11)
  Hispanic 7 (0.6%) -
  international 8 (0.6%) -
  Pacific islander 2 (0.1%) -
  not recorded 307 (24.2%) -
 academic status p = 0.70
  undergraduate student (reference group) 1153 (90.8%) -
  graduate student 101 (7.9%) 0.83 (0.52-1.30)
  spouse/dependent 4 (0.3%) -
  not recorded 12 (0.9%) -
 height (inches) 1242 (97.8%) 1.03 (1.00-1.07) p = 0.04*
 weight (pounds) 1236 (97.3%) 1.00 (0.99-1.01) p = 0.15
Visit Characteristics
 provider 1254 (98.7%) range 0.07 -3.27 p < 0.001**
 onset duration (patient reported) 1250 (98.4%) 0.99 (0.99-1.00) p < 0.001**
 severity (patient reported) p = 0.02*
  mild (reference group) 69 (5.4%) -
  moderate 381 (30.0%) 0.54 (0.32-0.95)
  severe 37 (2.9%) 1.20 (0.52-2.72)
  not recorded 783 (61.6%) -
 timing (patient reported) p < 0.001**
  stable/no change (reference group) 322 (25.3%) -
  worsening 370 (29.1%) 2.59 (1.84-3.65)
  improving 176 (13.8%) 0.67 (0.40-1.09)
  not recorded 402 (31.6%) -
 antibiotics in past month 85 (6.7%) 0.44 (0.23-0.77) p = 0.006**
Additional Diagnosis
 URI 216 (17.0%) 0.30 (0.19-0.44) p < 0.001**
 suspicious cough 102 (8.0%) 1.30 (0.84-1.98) p = 0.22
 allergic rhinitis 38 (3.0%) 0.43 (0.16-0.96) p = 0.06
 fever 19 (1.5%) 2.13 (0.84-5.31) p = 0.10
 viral syndrome 15 (1.2%) - -
 tonsillitis 6 (0.4%) - -
 influenza 5 (0.4%) - -
 mononucleosis 7 (0.5%) - -
Common Symptoms Recorded†
 throat symptoms
  sore throat 459 (36.1%) 1.45 (1.13-1.86) p = 0.003**
  painful swallowing 146 (11.5%) 0.60 (0.39-0.89) p = 0.01*
  hoarseness 186 (14.6%) 0.84 (0.59-1.18) p = 0.32
  swollen glands in neck 126 (9.9%) 1.19 (0.80-1.75) p = 0.39
 systemic symptoms
  headache 272 (21.4%) 0.88 (0.65-1.18) p = 0.40
  documented fever 73 (5.7%) 0.63 (0.39-1.04) p = 0.06
  fever symptoms (patient reported) 285 (22.4%) 1.10 (0.83-1.46) p = 0.51
  chills 164 (12.9%) 0.86 (0.60-1.22) p = 0.38
  sweats 182 (14.3%) 1.02 (0.73-1.45) p = 0.92
 nasal symptoms
  stuffy nose 782 (61.6%) 1.04 (0.81-1.33) p = 0.76
  sinus congestion 402 (39.0%) 0.83 (0.64-1.08) p = 0.16
  clear nasal discharge 251 (19.8%) 0.86 (0.63-1.16) p = 0.33
  purulent nasal discharge 212 (16.7%) 0.96 (0.69-1.32) p = 0.79
  post-nasal drip sensation 444 (35.0%) 1.10 (0.86-1.41) p = 0.46
  sinus pain 85 (6.7%) 1.79 (1.14-2.79) p = 0.01*
  sneezing 108 (8.5%) 0.47 (0.28-0.77) p = 0.004**
 pulmonary symptoms
  sleep disruption due to cough 710 (55.9%) 1.08 (0.85-1.37) p = 0.54
  sputum production 743 (58.5%) 0.94 (0.73-1.20) p = 0.61
  shortness of breath 412 (32.4%) 0.69 (0.53-0.88) p = 0.003**
  chest tightness 331 (26.1%) 0.82 (0.62-1.07) p = 0.14
  wheezing 340 (26.8%) 0.64 (0.49-0.84) p = 0.001**
  chest pain 269 (21.2%) 0.75 (0.56-0.99) p = 0.047*
  paroxysms of cough 362 (28.5%) 0.91 (0.70-1.18) p = 0.46
 ear symptoms
  ear pain 59 (4.6%) 1.03 (0.57-1.78) p = 0.93
  ear pressure sensation 143 (11.2%) 0.93 (0.63-1.36) p = 0.71
  decreased hearing 41 (3.2%) 0.96 (0.47-1.87) p = 0.92
 GI symptoms
  loss of appetite 146 (11.5%) 0.80 (0.53-1.17) p = 0.26
  abdominal pain 29 (2.3%) 0.26 (0.06-0.75) p = 0.03*
  post-tussive vomiting 85 (6.7%) 0.59 (0.38-0.92) p = 0.02*
  nausea 72 (5.7%) 0.50 (0.26-0.89) p = 0.02*
  vomiting 58 (4.6%) 0.73 (0.38-1.32) p = 0.32
  diarrhea 37 (2.9%) 1.27 (0.62-2.49) p = 0.49
 neuro-vascular symptoms
  lightheadedness 59 (4.6%) 1.30 (0.74-2.24) p = 0.33
Commonly Ordered Labs
 chest x-ray 223 (17.6%) 2.17 (1.61-2.91) p < 0.001**
 rapid strep screen 37 (2.9%) 0.54 (0.21-1.16) p = 0.14
 complete blood count 115 (9.0%) 1.38 (0.92-2.06) p = 0.11
 monospot 36 (2.8%) 1.33 (0.65-2.61) p = 0.41
 influenza A + B 19 (1.5%) 0.27 (0.04-0.95) p = 0.08
Common Exam Findings†
 ear exam
  tympanic membrane (TM) bulging 32 (2.5%) 0.07 (0.004-0.34) p = 0.01*
  TM retraction 48 (3.8%) 0.77 (0.38-1.46) p = 0.44
  visible fluid behind TM 173 (13.6%) 0.18 (0.10-0.30) p < 0.001**
  cerumen in canal 37 (2.9%) 0.64 (0.27-1.34) p = 0.26
 nose exam
  mucosal edema 707 (55.7%) 0.83 (0.65-1.06) p = 0.14
  mucosal erythema 606 (47.7%) 0.80 (0.63-1.02) p = 0.07
  nasal discharge 382 (30.1%) 1.58 (1.22-2.04) p < 0.001**
  maxillary sinus tenderness 35 (2.7%) 2.01 (1.01-3.95) p = 0.04*
 throat exam
  erythema 240 (18.9%) 0.76 (0.55-1.04) p = 0.09
  lymphoid hyperplasia 114 (9.0%) 1.59 (1.07-2.36) p = 0.02*
  post-nasal drip 181 (14.2%) 1.41 (1.01-1.95) p = 0.04*
 tonsil exam
  surgically absent 56 (4.4%) 0.93 (0.50-1.65) p = 0.81
  erythema 97 (7.6%) 0.47 (0.27-0.79) p = 0.006**
  enlarged 57 (4.5%) 1.10 (0.62-2.04) p = 0.74
 lymphatics exam
  anterior cervical lymphadenopathy, tender 64 (5.0%) 1.88 (1.12-3.12) p = 0.01*
  anterior cervical lymphadenopathy, non-tender 103 (8.1%) 0.81 (0.51-1.27) p = 0.38
  posterior cervical lymphadenopathy, non-tender 62 (4.9%) 0.67 (0.35-1.20) p = 0.19
  anterior cervical lymphadenopathy 132 (10.4%) 2.80 (1.94-4.04) p < 0.001**
  posterior cervical lymphadenopathy 38 (3.0%) 1.08 (0.52-2.12) p = 0.83
 lung exam
  wheezing 253 (19.9%) 1.82 (1.37-2.43) p < 0.001**
  rales 22 (1.7%) 8.26 (3.24-25.27) p < 0.001**
  rhonchi 273 (21.5%) 2.30 (1.74-3.03) p < 0.001**
  percussion abnormality 30 (2.4%) 9.89 (4.27-26.89) p < 0.001**

includes symptoms and findings recorded for > 20 visits

Table 4.

Factors independently associated with prescribing in a multivariate model

Variable Odds Ratio (95% CI) p-value
Visit and Patient Characteristics
 visit date (days) 0.99 (0.99-0.99) p < 0.001**
 height (inches) 1.05 (1.00-1.09) p = 0.03*
 provider range 0.04-8.42 p < 0.001**
 onset duration (days) 1.04 (1.03-1.05) p < 0.001**
 progression
  stable/no change (reference group)
  worsening 1.79 (1.11-2.90) p = 0.02*
  improving 0.43 (0.23-0.81) p = 0.01*
  not recorded 1.43 (0.83-2.48) p = 0.20
 antibiotics in past month 0.32 (0.14-0.65) p = 0.003**
Diagnosis
 URI diagnosis 0.36 (0.21-0.62) p < 0.001**
Symptoms
 sore throat 1.46 (1.04-2.05) p = 0.03*
 sneezing 0.48 (0.22-0.97) p = 0.048*
Exam Findings
 lymphatics
  anterior cervical lymphadenopathy, tender 2.55 (1.27-5.13) p = 0.008**
  anterior cervical lymphadenopathy 2.88 (1.55- 5.39) p < 0.001**
 lungs
  rales 10.21 (3.16-60.02) p < 0.001**
  rhonchi 5.08 (3.10-8.49) p < 0.001**
  percussion abnormality 9.69 (3.47-30.79) p < 0.001**

Authors’ contributions

VJM analyzed the data and wrote the manuscript. EPCF and RRV were major contributors to data collection and processing. YZ assisted with literature review and manuscript writing. MZ, AFR, and ELM conceived, designed, and managed the study, and contributed substantially to manuscript writing. All authors read and approved the final manuscript.

Funding

This study was funded by the Huck Institutes of the Life Sciences at Pennsylvania State University. The funding body did not have a role in designing the study, in collection, analysis, and interpretation of data, or in writing the manuscript.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The Pennsylvania State University Institutional Review Board (IRB) approved this research. Honest brokers were employed and trained to access electronic medical records for clinical visits, extract deidentified data (data excluding information that could be used to identify individual patients), and enter it in the secure database manager REDCap for use by the researchers. Informed consent was waived by the IRB given the retrospective nature of the study and the use of honest brokers for deidentification.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among U.S. ambulatory care visits, 2010-2011. JAMA. 2016;315(17):1864–1873. doi: 10.1001/jama.2016.4151. [DOI] [PubMed] [Google Scholar]
  • 2.Pew Research Center. Antibiotic use in outpatient settings. Washington D.C: The Pew Chartible Trusts; 2016.
  • 3.Friedman ND, Temkin E, Carmeli Y. The negative impact of antibiotic resistance. Clin Microbiol Infect. 2016;22(5):416–422. doi: 10.1016/j.cmi.2015.12.002. [DOI] [PubMed] [Google Scholar]
  • 4.Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176–187. doi: 10.1016/S0140-6736(15)00473-0. [DOI] [PubMed] [Google Scholar]
  • 5.zur Wiesch PA, Kouyos R, Engelstädter J, Regoes RR, Bonhoeffer S. Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis. 2011;11(3):236–247. doi: 10.1016/S1473-3099(10)70264-4. [DOI] [PubMed] [Google Scholar]
  • 6.The White House . National action plan for combating antibiotic-resistant bacteria. 2015. [Google Scholar]
  • 7.Barnett ML, Linder JA. Antibiotic prescribing for adults with acute bronchitis in the United States, 1996-2010. JAMA. 2014;311(19):2020–2022. doi: 10.1001/jama.2013.286141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Brown DW, Taylor R, Rogers A, Weiser R, Kelley M. Antibiotic prescriptions associated with outpatient visits for acute upper respiratory tract infections among adult Medicaid recipients in North Carolina. N C Med J. 2003;64(4):148–156. [PubMed] [Google Scholar]
  • 9.Schmidt ML, Spencer MD, Davidson LE. Patient, provider, and practice characteristics associated with inappropriate antimicrobial prescribing in ambulatory practices. Infect Control Hosp Epidemiol. 2018;39(3):307–315. doi: 10.1017/ice.2017.263. [DOI] [PubMed] [Google Scholar]
  • 10.Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA J Am Med Assoc. 1997;278(11):901. doi: 10.1001/jama.1997.03550110039033. [DOI] [PubMed] [Google Scholar]
  • 11.Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2017;6:CD000245. doi: 10.1002/14651858.CD000245.pub4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Talwalkar A, Hing E, Palso K. National Hospital Ambulatory Medical Care Survey: 2011 outpatient department summary tables. Hyattsville: U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics; 2011. [Google Scholar]
  • 13.Macfarlane J, Holmes W, Gard P, Macfarlane R, Rose D, Weston V, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001;56(2):109–114. doi: 10.1136/thorax.56.2.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR, et al. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Intern Med. 2001;134(6):521. doi: 10.7326/0003-4819-134-6-200103200-00021. [DOI] [PubMed] [Google Scholar]
  • 15.Irwin RS, Baumann MH, Bolser DC, Boulet L-P, Braman SS, Brightling CE, et al. Diagnosis and management of cough executive summary. Chest. 2006;129(1):1S–23S. doi: 10.1378/chest.129.1_suppl.1S. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Grigoryan L, Zoorob R, Shah J, Wang H, Arya M, Trautner BW. Antibiotic prescribing for uncomplicated acute bronchitis is highest in younger adults. Antibiotics. 2017;6(4):E22. doi: 10.3390/antibiotics6040022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Xu KT, Roberts D, Sulapas I, Martinez O, Berk J, Baldwin J. Over-prescribing of antibiotics and imaging in the management of uncomplicated URIs in emergency departments. BMC Emerg Med. 2013;13(1):7. doi: 10.1186/1471-227X-13-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Aspinall SL, Good CB, Metlay JP, Mor MK, Fine MJ. Antibiotic prescribing for presumed nonbacterial acute respiratory tract infections. Am J Emerg Med. 2009;27(5):544–551. doi: 10.1016/j.ajem.2008.04.015. [DOI] [PubMed] [Google Scholar]
  • 19.Donnelly JP, Baddley JW, Wang HE. Antibiotic utilization for acute respiratory tract infections in U.S. emergency departments. Antimicrob Agents Chemother. 2014;58(3):1451–1457. doi: 10.1128/AAC.02039-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.McKay R, Mah A, Law MR, McGrail K, Patrick DM. Systematic review of factors associated with antibiotic prescribing for respiratory tract infections. Antimicrob Agents Chemother. 2016;60(7):4106–4118. doi: 10.1128/AAC.00209-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Antibiotic use in the United States . 2018 Update: Progress and opportunities. Atlantia: US Department of Health and Human Services, CDC; 2019. [Google Scholar]
  • 22.Dobson EL, Klepser ME, Pogue JM, Labreche MJ, Adams AJ, Gauthier TP, et al. Outpatient antibiotic stewardship: interventions and opportunities. J Am Pharm Assoc. 2017;57(4):464–473. doi: 10.1016/j.japh.2017.03.014. [DOI] [PubMed] [Google Scholar]
  • 23.Drekonja DM, Filice GA, Greer N, Olson A, MacDonald R, Rutks I, et al. Antimicrobial stewardship in outpatient settings: a systematic review. Infect Control Hosp Epidemiol. 2015;36(2):142–152. doi: 10.1017/ice.2014.41. [DOI] [PubMed] [Google Scholar]
  • 24.Gerber JS, Prasad PA, Fiks AG, Localio AR, Grundmeier RW, Bell LM, et al. Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians a randomized trial. JAMA. 2013;309(22):2345–2352. doi: 10.1001/jama.2013.6287. [DOI] [PubMed] [Google Scholar]
  • 25.Avorn J, Solomon DH. Cultural and economic factors that (mis) shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med. 2000;133(2):128–135. doi: 10.7326/0003-4819-133-2-200007180-00012. [DOI] [PubMed] [Google Scholar]
  • 26.O’Connor R, O’Doherty J, O’Regan A, Dunne C. Antibiotic use for acute respiratory tract infections (ARTI) in primary care; what factors affect prescribing and why is it important? A narrative review. Ir J Med Sci. 2018;187(4):969–986. doi: 10.1007/s11845-018-1774-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Whaley LE, Businger AC, Dempsey PP, Linder JA. Visit complexity, diagnostic uncertainty, and antibiotic prescribing for acute cough in primary care: a retrospective study. BMC Fam Pract. 2013;14(1):120. doi: 10.1186/1471-2296-14-120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gonzales R, Camargo CA, MacKenzie T, Kersey AS, Maselli J, Levin SK, et al. Antibiotic treatment of acute respiratory infections in acute care settings. Acad Emerg Med. 2006;13(3):288–294. doi: 10.1197/j.aem.2005.10.016. [DOI] [PubMed] [Google Scholar]
  • 29.Gonzales R, Barrett PH, Crane LA, Steiner JF, Steiner JF. Factors associated with antibiotic use for acute bronchitis. J Gen Intern Med. 1998;13(8):541–548. doi: 10.1046/j.1525-1497.1998.00165.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Snyder TD, de Brey C, Dillow S. Digest of education statistics: 2017. Washington, DC: National Center for Educational Statistics, US Department of Education, Institute of Education Sciences; 2019. [Google Scholar]
  • 31.Turner JC, Keller A. College health surveillance network: epidemiology and health care utilization of college students at us 4-year universities. J Am Coll Heal. 2015;63(8):530–538. doi: 10.1080/07448481.2015.1055567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Atkinson I. Accuracy of data transfer: double data entry and estimating levels of error. J Clin Nurs. 2012;21(19pt20):2730–2735. doi: 10.1111/j.1365-2702.2012.04353.x. [DOI] [PubMed] [Google Scholar]
  • 33.Day S, Fayers P, Harvey D. Double data entry: what value, what price? Control Clin Trials. 1998;19(1):15–24. doi: 10.1016/S0197-2456(97)00096-2. [DOI] [PubMed] [Google Scholar]
  • 34.Barchard KA, Pace LA. Preventing human error: the impact of data entry methods on data accuracy and statistical results. Comput Human Behav. 2011;27(5):1834–1839. doi: 10.1016/j.chb.2011.04.004. [DOI] [Google Scholar]
  • 35.Hosmer David W., Lemeshow Stanley, Sturdivant Rodney X. Applied Logistic Regression. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2013. [Google Scholar]
  • 36.Zuckerman IH, Perencevich EN, Harris AD. Concurrent acute illness and comorbid conditions poorly predict antibiotic use in upper respiratory tract infections: a cross-sectional analysis. BMC Infect Dis. 2007;7:47. doi: 10.1186/1471-2334-7-47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Dempsey PP, Businger AC, Whaley LE, Gagne JJ, Linder JA. Primary care clinicians’ perceptions about antibiotic prescribing for acute bronchitis: a qualitative study. BMC Fam Pract. 2014;15(1):194. doi: 10.1186/s12875-014-0194-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Meeker D, Linder JA, Fox CR, Friedberg MW, Persell SD, Goldstein NJ, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices a randomized clinical trial. J Am Med Assoc. 2016;315(6):562–570. doi: 10.1001/jama.2016.0275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Hemkens LG, Saccilotto R, Reyes SL, Glinz D, Zumbrunn T, Grolimund O, et al. Personalized prescription feedback using routinely collected data to reduce antibiotic use in primary care a randomized clinical trial. JAMA Intern Med. 2017;177(2):176–183. doi: 10.1001/jamainternmed.2016.8040. [DOI] [PubMed] [Google Scholar]
  • 40.Klepser Donald G., Klepser Michael E., Dering-Anderson Allison M., Morse Jacqueline A., Smith Jaclyn K., Klepser Stephanie A. Community pharmacist–physician collaborative streptococcal pharyngitis management program. Journal of the American Pharmacists Association. 2016;56(3):323-329.e1. doi: 10.1016/j.japh.2015.11.013. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets analyzed during the current study are available from the corresponding author on reasonable request.


Articles from BMC Infectious Diseases are provided here courtesy of BMC

RESOURCES